Phase 1/2 trial of single‐session stereotactic body radiotherapy for previously unirradiated spinal metastases
Open accessThe DOI matches its Crossref record.
Abstract
BACKGROUND: In this phase 1/2 study, the authors tested the hypothesis that single‐fraction stereotactic body radiotherapy (SBRT) for previously unirradiated spinal metastases is a safe, feasible, and efficacious treatment approach. METHODS: All patients were evaluated by a multidisciplinary team. Spinal magnetic resonance imaging studies were obtained before treatment and at regular intervals to define both target volume and response to treatment. SBRT was delivered to a peripheral dose of 16 to 24 grays in a single fraction while limiting the dose to the spinal cord. Higher doses were used for renal cell histology. The National Cancer Institute Common Toxicity Criteria 2.0 and McCormick neurologic function score were used as toxicity assessment tools. RESULTS: In total, 61 patients who had 63 tumors of the noncervical spine were enrolled and received SBRT between 2005 and 2010 on a prospective, phase 1/2 trial at The University of Texas M. D. Anderson Cancer Center. The mean follow‐up was 20 months. The actuarial 18‐month imaging local control rate for all patients was 88%, the actuarial 18‐month overall survival rate for all patients was 64%, and the median survival for all patients was 30 months. No significant differences in outcomes were noted with respect to tumor histology or SBRT dose. Two patients experienced radiation adverse events (grade 3 or higher). The actuarial rate of 18‐month freedom from neurologic deterioration from any cause was 82%. CONCLUSIONS: Data from this phase 1/2 trial supported an expanded indication for SBRT as first‐line treatment of spinal metastases in selected patients. The authors concluded that additional studies that can prospectively identify predictive factors for spinal cord toxicity after SBRT are warranted to minimize the incidence of this serious yet rare complication. Cancer 2012. © 2012 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Spratt, D. E., Beeler, W. H., de Moraes, F. Y., Rhines, L. D., Gemmete, J. J., Chaudhary, N., Shultz, D. B., Smith, S. R., Berlin, A., Dahele, M., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30612-5 · Cited by 363
Self-citationLehrer, E. J., Singh, R., Wang, M., Chinchilli, V. M., Trifiletti, D. M., Ost, P., Siva, S., Meng, M.-B., Tchelebi, L., & Zaorsky, N. G. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2020.6146 · Cited by 196
Immunological off-target effects of imatinib
Zitvogel, L., Rusakiewicz, S., Routy, B., Ayyoub, M., & Kroemer, G. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.41 · Cited by 142
Metadata
- Authors
- Garg, A. K., Shiu, A. S., Yang, J., Wang, X., Allen, P., Brown, B. W., Grossman, P., Frija, E. K., McAleer, M. F., Azeem, S., Brown, P. D., Rhines, L. D., & Chang, E. L.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2012-04-17
- Volume
- 118
- Issue
- 20
- Pages
- 5069-5077
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W1589157904
- Cited by
- 210
- References
- 0
- FWCI
- 13.83
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.